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Abstract
Background: Ahmed and Baerveldt implants have already have been established for treating refractory glaucoma,
however, to date, their outcome in Malayan eyes has not yet been reported. This study aimed to evaluate a comparison of
the success rate between Ahmed and Baerveldt implants surgical intervention in Malayan patients with glaucoma.
Methods: A descriptive retrospective study was conducted at Cipto Mangunkusumo Hospital, Indonesia, from January
2013 to December 2015. All glaucoma patients who underwent Ahmed and Baerveldt implants and intraocular pressure
(IOP), and presented for follow-up evaluation one year post implant, were enrolled in this study. Visual acuity and
complications were also recorded. A comparison between the two groups was then analysed. Results: The study cohort
included a total of 117 glaucoma patients eyes, of which 64 and 53 received the Ahmed and Baerveldt implants,
respectively. The pre-operation IOP between the two groups was found to be significantly different (p = 0.01), but no
significant difference (p = 0.24) was observed after surgery, although both groups showed a declining IOP. Complete
success was achieved in 75% of Ahmed and 60.38% of Baerveldt implant patients. Overall, 9 patients developed
complications. Conclusions: Both the Ahmed and Baerveldt implant groups demonstrated similar success in reducing IOP.
Keywords: glaucoma, intraocular pressure, implant

possibility of post-surgical hypotonia. However, some
complications such as a shallow anterior chamber, choroidal effusion and suprachoroidal bleeding may occur.
The valveless Baerveldt implant requires an initial flow
restriction to provide adequate time for bleb formation.
Although the Baerveldt implant has been reported to
cause an initial hypertensive state and fluctuating IOP,
they are fewer complications of encapsulation and the
necessity to administrate post-operative antiglaucoma
medication. Furthermore, a more optimal controlled
long-term IOP has been reported to the Ahmed implant.
However, it has been proved that the Baerveldt implant
may have a higher risk of hypotonia since it has no
valves and has a high flow rate of aqueous humour
drainage.5-7 It should also be considered that implant
success depends on the selection of appropriate
candidates. Thus, it is imperative to carry out extensive
identification and evaluation of patient characteristics
when selecting the type of glaucoma implants to ensure
a successful outcome. The global variation of patient
profiles has led us to question the patient characteristics
and success rate of glaucoma implants at Cipto
Mangunkusumo Hospital (RSCM Kirana). The aim of
this study was to evaluate a comparison of the success
rate of Ahmed vs. Baerveldt implant surgery in Malayan
glaucoma patients.

Introduction
Glaucoma is a progressive optic neuropathy which
causes associated visual field loss with increased
intraocular pressure (IOP) as the main risk factor.
Management of glaucoma consists of antiglaucoma
medication and surgical approach, if necessary. The two
common options for glaucoma surgery are conventional
standard surgery of trabeculectomy, and implantation of
glaucoma drainage device surgery. Glaucoma implants
are commonly employed in glaucoma in management
to create a bypass, thus facilitating the drainage of
aqueous humour through a small tube to the
subconjunctival area as far as 8 mm from the corneal
limbus.1-3 Anthony Molteno was the first person to
introduce the glaucoma implant using conventional
standard surgery for the treatment of glaucoma cases
with a high risk of treatment failure. Since then, various
types of implants are commercially available.4
Currently, the two implants most often utilised are the
Ahmed and Baerveldt implants. The Ahmed implant
uses venture-based technology with a valve that has
been designed to open when the IOP is more than 18
mmHg and close when the IOP is less than 18 mmHg.
This mechanism of action also minimises the
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Methods
A descriptive retrospective study design was chosen. The
study was conducted at RSCM Kirana between January
2013 and December 2015. Approval for the study was
obtained from the Ethics Committee, Faculty of Medicine
Universitas Indonesia (0987/UN2.F1/ETIK/2018). The
inclusion criteria incor-porated all glaucoma patients
who had received an Ahmed or Baerveldt glaucoma
implant and whose IOP had been evaluated for one year
thereafter. Patients were excluded from the study if
there was incomplete data or if they failed to turn up for
a follow-up visit during the year after receiving the
implant. The initial patient selection was finalised
according to individual glaucoma patients’ medical
records stored in the medical record files room at RSCM
Kirana. Prior to the surgical procedure, the patients gave
signed consent according to the Helsinki declaration. All
important information variables were then documented in
the master table. This included the patient’s age at initial
treatment, gender, diagnosis and clinical data such as
visual acuity (logMAR), initial IOP, history of using
antiglaucoma medication and laser or any eye surgeries
prior to the procedure. IOP data, and glaucoma implant
procedure complications were recorded and analysed at
1, 3, 6, and 12 months following the glaucoma implant
procedure.
Glaucoma Implant Surgical Techniques. The surgical
glaucoma implant procedure was performed at RSCM
Kirana by four expert glaucoma surgeons: WA, V, SM
and AS. All glaucoma implant procedures involved the
installation of either a 350 mm2 Baerveldt implant
(Advanced Medical Optics, Santa Ana, CA, USA) or a
184 mm2 single plate Ahmed implant (New World
Medical, Rancho Cucamonga, CA, USA).8,9 The procedure
commenced by creating a fornix-based conjunctival
incision in the supra-temporal quadrant of the eye. For
both implants, placement was approximately 8–10 mm
from the limbus and they were fixated at the episclera
using nylon 10.0 sutures. The lateral edge of the
Baerveldt implant was placed under the lateral rectus,
and the medial edge was inserted under the medial
rectus muscle. The tube next to the plate was tightly
ligated using vicryl 7.0 sutures. Once it was confirmed
that there was no water leakage into the plate a slit was
made in front of the ligation for drainage of fluid.
In both surgeries, a paracentesis was made, and a
viscoelastic was inserted into the anterior chamber of
the eye. Next, the point of the tube was cut bevel-up
approximately 2 mm long in anterior chamber close to
the limbus. A guiding pathway was made using a 23
gauge needle, and the tube was directly inserted parallel
to the iris towards the anterior chamber. The tube was
fixated above the sclera using nylon 10.0 sutures,
covered with donor sclera to prevent exposed tube and
fixated on the sclera using vicryl 8.0. The exposed
Makara J. Health Res.

conjunctiva and subtenon conjunctiva were then sutured
at the limbus with vicryl 8.0. After the procedure was
completed, the patient was given antibiotic and steroid
eye drops to be administered for two months.
The implant procedure was considered a complete
success if there was a controlled IOP < 21 mmHg over
two consecutive visits during the last 12-months’ postsurgical follow-up, the patient did not need glaucoma
medication, and the loss of visual acuity was not more
than two lines of the Snellen chart. A qualified success
was defined as a controlled IOP < 21 mmHg over two
consecutive visits during the last 12-months’ post-surgical
follow-up and the use of one or more antiglaucoma
medications.10 The procedure was considered failed
when the IOP > 21 mmHg. The evaluated variables
were analysed using SPSS 22.0 software (IBM Corp.,
Armonk, NY, USA). Numerical and categorical variables
were evaluated by unpaired t-tests and chi square tests,
respectively.

Results
The patient characteristics are presented in Table 1. A
total of 117 eyes from glaucoma patients were included
in this study. There were 52 male patients and 106 eyes
belonging to patients >30 years old. Sixty-four eyes
received the Ahmed implant, and the remaining 53 eyes
received the Baerveldt implant. There were 11 cases of
congenital glaucoma, 15 of primary glaucoma, and 91
of secondary glaucoma. All the congenital glaucoma
cases received the Ahmed implant, while the Baerveldt
implant was given to 51/91 secondary glaucoma patients.
The mean IOP prior to and one year post surgery was
recorded and analysed for all glaucoma implant patients.
Prior to surgery a significant difference (p = 0.01) was

Figure 1. Intraocular pressure reduction in the ahmed and
baerveldt glaucoma implant groups before surgery until one
year post surgery
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observed in the mean IOP of the Ahmed implant group
(36.65  1.30 mmHg, range 27–70 mmHg) compared to
the Baerveldt implant group (46.61  1.37 mmHg, range
23–70 mmHg). Furthermore, the mean IOP at one year
post surgery decreased by 69.98% to 15.67  1.16
mmHg in the Ahmed group and by 74.25% to 13.11 
4.37 mmHg in the Baerveldt group, but this was not
significant (p = 0.24) (Table 2). A graph showing the
IOP reduction over time is presented in Figure 1. The
complete success rate of the Ahmed and Baerveldt
implants was 48 (75%) and 32 (60.38%) eyes,
respectively (p = 0.28). A qualified success with the
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Ahmed and Baerveldt implants was achieved in 6
(9.38%) and 15 (28.30%) eyes, respectively (p = 0.05).
The implant procedure failed in 10 (15.63%) Ahmed
implant eyes and 6 (11.32%) Baerveldt implant eyes (p =
0.72) (Table 3). Table 4 presents the comparison between
the two groups regarding complications, visual acuity,
and the adminis-tration of antiglaucoma medication after
implant surgery. Surprisingly, only 9 patients developed
complications. Moreover, patients in the Baerveldt
group required more antiglaucoma drugs compared to
Ahmed group. The visual acuity of both groups
remained stable.

Table 1. Patient Characteristics
Variables
Gender
Male
Female

Ahmed Implant
n = 64 eyes

Baerveldt Implant
n = 53 eyes

Results
n = 117 eyes

32
32

20
33

52
65

Age
<30
>31

11
106

Type of Glaucoma
Congenital Glaucoma
Primary Glaucoma
Secondary Glaucoma

11
12
40

11
15
91

3
51

Table 2. Intraocular Pressure Comparison Before and After Glaucoma Implant Surgery
Variables
IOP Pre Operation (mmHg)
Mean  SD
Median  SD
Range
IOP Post Operation (mmHg)
Mean  SD
Median  SD
% IOP reduction
IOP: Intraocular pressure.
*p < 0.05 (unpaired t-test).

Ahmed
n = 64

Baerveldt
n = 53

36.65  1.30
35.00  1.30
27–70

46.61  1.37
46.00  1.37
23–70

0.01*

15.67  1.16
11.00  1.16
69.98%

13.11  4.34
12.00  4.34
74.25%

0.24

p

Table 3. Comparison between end results of Ahmed and Baerveldt implant surgeries
End Results
Complete Success
Relative Success
Failure
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Ahmed Implant (%)
n = 64
48 (75%)
6 (9.38%)
10 (15.63%)

Baerveldt Implant (%)
n = 53
32 (60.38%)
15 (28.30%)
6 (11.32%)

p
0.28
0.05
0.72
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Table 4. Comparison in complications, visual acuity, and antiglaucoma administration after Glaucoma implant surgery
Ahmed Implant
Visual acuity
Better
No change
Worse

Baerveldt Implant

5
58
1

5
45
3

Number of antiglaucoma medications used
One
Two
Three

0
5
1

5
9
1

Complications
Hyphema
Choroidal effusion
Exposed tube
Clogged tube

0
0
1
2

1
1
2
2

Discussion
The results of our study show that in most cases both the
Ahmed and Baerveldt implants resulted in a satisfying
IOP reduction. However, the implant devices caused
vision loss in several instances, particularly in glaucoma
patients with a difficult diagnosis such as neovascular
glaucoma and inflammatory glaucoma. In these cases,
the vision loss was not only due to the implant itself but
also to the severity of the glaucoma diseases. It appears
that the Ahmed implant had a higher complete success
rate compared to the Baerveldt implant, but this was not
statistically significant and correlates with the results of
Tsai et al.5 Currently, the utilisation of glaucoma implants
is growing in popularity in terms of the high success
rate of the surgical procedure for refractory glaucoma,
especially due to better efficacy in lowering IOP over a
periode of time compared to trabeculectomy with or
without antimetabolites.7,10-13 Generally, glaucoma implants
are indicated for aphakic and pseudophakic glaucoma,
neovascular glaucoma, post-trabeculectomy glaucoma,
iridocorneal endothelial syndrome (ICE), uveitic glaucoma
and post-traumatic secondary glaucoma. Moreover,
glaucoma implants are also considered effective for
post-keratoplasty glaucoma, secondary glaucoma after
retinal procedures and paediatric glaucoma.2,12
Following the glaucoma implant procedure, scar tissue
around the implant plate forms within a number of weeks
and aqueous humour congregates in the cavity between
the implant plate and adjacent tissues.10 Subsequently, the
aqueous humour passively diffuses through the capsule
and is absorbed into the periocular capillaries. Fibrosis
occurs in the capsule surrounding the implant plate because
it has the highest resistance against aqueous humour
drainage. Therefore, the magnitude of IOP reduction often
depends on the thickness of the capsule and the surface
area of encapsulation and the size of the implant plate.
Makara J. Health Res.

A lower IOP is expected in cases of thinner capsules
with a wider surface area of encapsulation.10
There are various types of glaucoma implants based on
implant size, form, implant plate material and the presence
or absence of valves.1,7 In Indonesia, the most commonly
used implants are the Ahmed-184 and Baerveldt-350
implant. The Ahmed implant is considered the most
favourable for a number of reasons; namely , this surgical
procedure is less complex, a valve is used and fewer
complications arise. However, its effectiveness in lowering
IOP is relatively poor in cases of refractory glaucoma
with a higher IOP. Therefore, surgeons tend to opt for
Baerveldt implant which does not have valve. Following
the procedure the Baerveldt implant group required a
greater amount of additional antiglaucoma medication
compared to the Ahmed implant group due to the fact
that the case selection was performed for patients with a
more severe glaucoma condition with a higher risks for
failed trabeculectomy surgery. This study showed that
initial IOP in Baerveldt implant group was higher when
compare to Ahmed implant group.
The visual acuity after the implant procedures in both
groups was also similar. Most patients had persistent
visual acuity, and only a small percentage demonstrated
improved visual acuity. Lower visual acuity was observed
in both implant groups and included patients with
neovascular glaucoma. This clearly demonstrates ongoing
progressive retinal ischaemia despite adequate treatment,
and patients with ICE syndrome, who had advanced
glaucoma. These types of glaucoma are extremely difficult
to manage and usually result in permanent blindness.
Intra-operative complications of glaucoma implants
such as bleeding, exposed tube and false insertion of the
tube with subsequent leakage around the tube have been
frequently reported, similar to the results obtained in our
study.5 The most common post-operative complications
December 2018 | Vol. 22 | No. 3
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in our study were tube blockage and exposed tube. Tube
block is usually caused by a fibrin, vitreous or blood occlusion. All patients with a clogged tube showed improved
IOP after the tube had been flushed. An exposed tube is
frequently caused by mechanical injury to the conjunctiva
tissue due to direct contact with the implant tube and
can cause consequent erosion of the tube.

glaucoma eyes with poor prognosis which have a higher
risk to experience failed trabeculectomy surgery.

The routine use of a sclera or pericardium patch graft
can lower the risk of an exposed tube by 2%–7%.9 The
development of an exposed tube frequently occurs in
glaucoma implant patients with poor peribulbar conjunctiva tissue due to various previous surgical procedures
such as retinal surgery.9,11 One case of unresolved
hyphema was observed within 5 days following the
implant surgery. The patient sub-sequently underwent
irrigation and coagulum aspiration. Thereafter, the IOP
was well-controlled during the post-operative follow-up.
There was also a patient with choroidal effusion within
one week following surgery in the Baerveldt implant
group. This was spontaneously resolved with the increased
IOP. One patient in the Baerveldt implant group with
neovascular glaucoma underwent an additional implant
procedure.

Conflict of Interest

Overall, our study has demonstrated the relatively safe
utilisation of Ahmed and Baerveldt glaucoma implants
with satisfying results, correlating with the results of
studies in other Asian and non-Asian groups.12-17 Previous
study revealed a different pattern of wound healing
between the bleb in the glaucoma implant and the bleb
in trabeculectomy in Asian individuals, where the bleb
on the implant was less susceptible to the response of
more aggressive wound healing in Asian patients.14
Further studies are necessary for clarification. One
limitation of this study was that it was retrospective.
There was also biased criteria regarding the type of
implant selected, where the Baerveldt implant was used
in a greater number of poor prognosis glaucoma eyes
with higher IOP and in the more severe glaucoma cases,
such as neovascular glaucoma. The diameter plate in the
Baerveldt implant (350 mm) has a much more extensive
surface area when compared to Ahmed implant plate
(184 mm) and may accommodate aqueous humour in
subconjunctiva area. However, our evaluation of both
implant procedures indicate satisfying results and contribute to the additional benefits of glaucoma implants,
particularly in the management of refractory glaucomas,
such as neovascular glaucoma and glaucoma after
vitrectomy surgery.

Conclusions
In conclusion, both Ahmed and Baerveldt implants have
similar success rate in reducing IOP after the implant
procedure. However, the Baerveldt implant group was
found to require more antiglaucoma medication.
Furthermore, the group was used primarily to treat
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